Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Cash & Equivalents (2019 - 2025)

Vivos Therapeutics' Cash & Equivalents history spans 7 years, with the latest figure at $2.0 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $2.0 million for Q4 2025, down 67.59% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (down 67.59% YoY), and the annual figure for FY2025 was $2.0 million, down 67.59%.
  • Cash & Equivalents for Q4 2025 was $2.0 million at Vivos Therapeutics, down from $3.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $34.2 million in Q2 2021 to a low of $1.0 million in Q3 2023.
  • The 5-year median for Cash & Equivalents is $6.3 million (2024), against an average of $9.5 million.
  • The sharpest move saw Cash & Equivalents crashed 85.34% in 2022, then soared 531.1% in 2024.
  • Year by year, Cash & Equivalents stood at $24.0 million in 2021, then crashed by 85.34% to $3.5 million in 2022, then plummeted by 53.31% to $1.6 million in 2023, then skyrocketed by 281.01% to $6.3 million in 2024, then plummeted by 67.59% to $2.0 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $2.0 million, $3.1 million, and $4.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.